HomeMarket NewsMicro Cap StocksRageX Therapeutics Sees Drop in Stock Price as Merger with Serina Therapeutics...

RageX Therapeutics Sees Drop in Stock Price as Merger with Serina Therapeutics Sparks Controversy

Actionable Trade Ideas

always free


Serina Therapeutics Inc, a privately held, clinical-stage biotechnology company, entered into a License Agreement under which Pfizer Inc PFE will license, on a non-exclusive basis, Serina’s POZ polymer technology.

Serina is focused on developing its proprietary POZ Platform drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics.

“We are excited about the license to Pfizer for its use of the POZ polymer technology in initial research and development activities,” stated Dr. Milton Harris, Executive Board Chair at Serina Therapeutics. “The license agreement represents an important milestone for Serina.”

In August, Serina Therapeutics announced a merger agreement with AgeX Therapeutics Inc AGE in an all-stock transaction. 

The combined company will continue under the Serina Therapeutics name and will focus on advancing the pipeline of small molecule drug candidates targeting central nervous system indications, enabled by the company’s proprietary POZ Platform delivery technology. 

According to data from Benzinga Pro, AgeX Therapeutics stock is trading lower on heavy volume, with a session volume of 9.9 million shares traded, compared to the trailing 100-day volume of 17.29k shares.

Price Action: AGE shares are down 28.3% at $0.42 on the last check Friday.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.